ArticleSchmerz (Berlin, Germany)2011
[Treatment and healthcare costs of fibromyalgia syndrome in Germany: analysis of the data of the Barmer health insurance (BEK) from 2008-2009].
Article in Schmerz (Berlin, Germany), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 5 syntheses or guidelines pooled it, 46 citations in OpenAlex.
- [Definition, classification, clinical diagnosis and prognosis of fibromyalgia syndrome : Updated guidelines 2017 and overview of systematic review articles].Schmerz (Berlin, Germany) · 2017Pooled it
- Selective serotonin reuptake inhibitors for fibromyalgia syndrome.The Cochrane database of systematic reviews · 2015Pooled it
- [Methodology of the development of the updated LONTS guidelines for long-term administration of opioids in noncancer pain].Schmerz (Berlin, Germany) · 2015Pooled it
- [Fibromyalgia syndrome. Definition, classification, clinical diagnosis and prognosis].Schmerz (Berlin, Germany) · 2012Guideline
- The role of antidepressants in the management of fibromyalgia syndrome: a systematic review and meta-analysis.CNS drugs · 2012Pooled it
- Evaluation of a self-management patient education program for patients with fibromyalgia syndrome: study protocol of a cluster randomized controlled trial.BMC musculoskeletal disorders · 2016Trial
- [Etiological factors in chronic widespread pain and/or fibromyalgia syndrome: subjective perspectives of patients, general practitioners and psychotherapists : A pilot study].Schmerz (Berlin, Germany) · 2025Article
- The Association of Pain Medication Usage and Quantitative Sensory Testing Outcomes in Fibromyalgia Patients: A Secondary Data Analysis.NeuroSci · 2025Article
- Combined Functional and Structural Imaging of White Matter Reveals Brain Connectivity Alterations in Fibromyalgia Patients.Journal of pain research · 2025Article
- Atrophy patterns in hippocampal subregions and their relationship with cognitive function in fibromyalgia patients with mild cognitive impairment.Frontiers in neuroscience · 2024Article
- Article
- Mild Water-Filtered Infrared-A Whole-Body Hyperthermia Reduces Pain in Patients with Fibromyalgia Syndrome-A Randomized Sham-Controlled Trial.Journal of clinical medicine · 2023Article
- [Methodology report of the 2017 guidelines on fibromyalgia syndrome].Schmerz (Berlin, Germany) · 2017Article
- [Twelve years of the S3 guideline Fibromyalgia Syndrome-a never-ending war?]Schmerz (Berlin, Germany) · 2017Article
- [Healthcare services research on pain in Germany. A survey].Schmerz (Berlin, Germany) · 2015Article
- [Recommendations of the updated LONTS guidelines. Long-term opioid therapy for chronic noncancer pain].Schmerz (Berlin, Germany) · 2015Review
- Complementary and alternative drug therapy versus science-oriented medicine.German medical science : GMS e-journal · 2015Article
- Assessing Cognitive and Psychomotor Performance in Patients with Fibromyalgia Syndrome.Pain and therapy · 2014Article
- Review of pharmacological therapies in fibromyalgia syndrome.Arthritis research & therapy · 2014Review
- [Administrative prevalence, treatment and costs of somatoform pain disorder. Analysis of data of the BARMER GEK for the years 2008-2010].Schmerz (Berlin, Germany) · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe data available on the types of treatment delivered and healthcare costs of fibromyalgia syndrome (FMS) patients in Germany are currently not representative. MATERIAL AND
methodsThe data from all 6,897,846 insured persons of the German statutory health insurance company Barmer Ersatzkasse (BEK) before the fusion with the Gmünder Ersatzkasse (GEK) were analyzed if more than 2 billing cases with the diagnosis M79.7 were found (FMS cases) in the 8 consecutive quarter years of 2007-2008. In these cases the types and costs of out-patient treatment as well as the operation and procedure key (OPS) classification of in-patient treatment in cases of any discharge diagnosis of FMS were analyzed.
resultsA diagnosis of FMS was recorded in 14,870 insured persons in out-patient care and in 6130 in-patients from 1(st) January 2008 to 31(st) December 2009. The 1-year prevalence of FMS diagnosis was 19,592 of the patients (0.3%). Non-steroidal agents were prescribed in 48%, weak opioids in 21% and strong opioids in 11% of the out-patients with FMS. Out-patient psychotherapy was conducted in 8% of the FMS cases. In 31% of the cases hospital treatment was carried out of which 14% received multicomponent therapy. The average healthcare costs were 4,331 <euro> per year.
conclusionThe data of the BEK document high healthcare costs and treatment which is mainly not in line with the recommendations of the German guidelines on the management of FMS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.